Retrospective Cohort Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Aug 27, 2022; 14(8): 754-764
Published online Aug 27, 2022. doi: 10.4240/wjgs.v14.i8.754
3D laparoscopic-assisted vs open gastrectomy for carcinoma in the remnant stomach: A retrospective cohort study
Di Wu, Qi-Ying Song, Xiong-Guang Li, Tian-Yu Xie, Yi-Xun Lu, Ben-Long Zhang, Shuo Li, Xin-Xin Wang
Di Wu, Medical School of Chinese PLA, Beijing 100853, China
Di Wu, Qi-Ying Song, Xiong-Guang Li, Tian-Yu Xie, Yi-Xun Lu, Ben-Long Zhang, Shuo Li, Xin-Xin Wang, Department of General Surgery, The First Medical Centre, Chinese PLA General Hospital, Beijing 100853, China
Author contributions: Wu D and Wang XX designed the experiment; Wu D and Song QY performed the experiment; Li XG and Xie TY collected data; Wu D, Lu YX and Zhang BL analyzed the data; Wu D and Li S created the tables and figures based on the data; Wu D wrote the initial draft; and Wang XX modified the draft.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Chinese PLA General Hospital, No. S-2022-090-01.
Conflict-of-interest statement: The authors have no funding and conflicts of interest to disclose.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xin-Xin Wang, MD, PhD, Assistant Professor, Chief Doctor, Department of General Surgery, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. 301wxx@sina.com
Received: February 19, 2022
Peer-review started: February 19, 2022
First decision: April 19, 2022
Revised: May 2, 2022
Accepted: August 1, 2022
Article in press: August 1, 2022
Published online: August 27, 2022
ARTICLE HIGHLIGHTS
Research background

Three-dimensional (3D) laparoscopy provides a 3D sense of depth and layering that allows surgeons to obtain a field of vision similar to open surgery. 3D laparoscopic techniques are gradually being applied in the treatment of carcinoma in the remnant stomach (CRS), but their clinical efficacy remains controversial.

Research motivation

There are limited reports and studies about the application of 3D laparoscopic-assisted techniques in the treatment of CRS. No study has shown whether 3D laparoscopic-assisted gastrectomy (3DLAG) is superior or non-inferior to open gastrectomy (OG) for CRS.

Research objectives

This study retrospectively collected the clinical data of 3DLAG and OG in the treatment of CRS, analyzed the short-term and long-term efficacy of the two methods, and provided a reference for the minimally invasive treatment of CRS.

Research methods

The authors retrospectively evaluated 84 patients with CRS who had undergone OG for carcinoma or 3DLAGC at the First Medical Center of Chinese PLA General Hospital from January 2016 to January 2021. The short-term and long-term outcomes were compared between the OG (n = 48) and 3DLAG (n = 36) groups.

Research results

Compared with the OG group, the 3DLAG group had less surgical trauma and faster recovery after surgery. However, the complication rate and intensive care unit admission rate were equivalent between the two groups. The 1-year overall survival (OS) and 3-year OS rates were similar between the two groups, which suggested comparable long-term survival results between the groups. Our research showed that 3DLAG for CRS can be promoted safely and effectively in selected patients.

Research conclusions

Compared with OG, 3DLAG for CRS can achieve better short-term efficacy and equivalent oncological results without increasing clinical complications.

Research perspectives

Prospective randomized controlled trials with large samples and multiple centers are needed in the future.